Φορτώνει......
5PSQ-026 Efficacy and safety of evolocumab in hypercholesterolaemia and mixed dyslipidaemia
BACKGROUND: The main goal in the therapy of lipids disorders is to prevent morbidity associated with cardiovascular mortality. Evolocumab is a new drug appropiate in reducing the cholesterol level in hypercholesterolaemia and mixed dyslipidaemia. PURPOSE: To describe the efficacy and safety of evolo...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Eur J Hosp Pharm |
|---|---|
| Κύριοι συγγραφείς: | , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
BMJ Group
2018
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7535229/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.380 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|